Literature DB >> 17245484

Early restenosis after drug-eluting stent implantation: A putative role for platelet activation.

Corrado Tamburino1, Gian Paolo Ussia, Marco Zimarino, Alfredo R Galassi, Raffaele De Caterina.   

Abstract

Drug-eluting stents (DES) reduce intimal hyperplasia and restenosis, but they also inhibit stent endothelization, making the vascular surface more thrombogenic. The present report describes two cases of in-stent restenosis after DES deployment at exactly the same sites where subacute stent thrombosis had occurred. Extremely careful follow-up is mandatory after the recognition of intraluminal thrombi inside DES because restenosis may occur at the same site of DES thrombosis.

Entities:  

Mesh:

Year:  2007        PMID: 17245484      PMCID: PMC2649173          DOI: 10.1016/s0828-282x(07)70214-3

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  12 in total

Review 1.  The comparative pathobiology of atherosclerosis and restenosis.

Authors:  J L Orford; A P Selwyn; P Ganz; J J Popma; C Rogers
Journal:  Am J Cardiol       Date:  2000-08-24       Impact factor: 2.778

2.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

Authors:  Eugène P McFadden; Eugenio Stabile; Evelyn Regar; Edouard Cheneau; Andrew T L Ong; Timothy Kinnaird; William O Suddath; Neil J Weissman; Rebecca Torguson; Kenneth M Kent; August D Pichard; Lowell F Satler; Ron Waksman; Patrick W Serruys
Journal:  Lancet       Date:  2004 Oct 23-29       Impact factor: 79.321

3.  Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.

Authors:  E Tsuchikane; A Fukuhara; T Kobayashi; M Kirino; K Yamasaki; T Kobayashi; M Izumi; S Otsuji; H Tateyama; M Sakurai; N Awata
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

4.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.

Authors:  R Gallo; A Padurean; T Jayaraman; S Marx; M Roque; S Adelman; J Chesebro; J Fallon; V Fuster; A Marks; J J Badimon
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

5.  Thrombosis modulates arterial drug distribution for drug-eluting stents.

Authors:  Chao-Wei Hwang; Andrew D Levin; Michael Jonas; Pamela H Li; Elazer R Edelman
Journal:  Circulation       Date:  2005-03-28       Impact factor: 29.690

6.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Authors:  Ioannis Iakovou; Thomas Schmidt; Erminio Bonizzoni; Lei Ge; Giuseppe M Sangiorgi; Goran Stankovic; Flavio Airoldi; Alaide Chieffo; Matteo Montorfano; Mauro Carlino; Iassen Michev; Nicola Corvaja; Carlo Briguori; Ulrich Gerckens; Eberhard Grube; Antonio Colombo
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

7.  Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)

Authors:  P W Serruys; B van Hout; H Bonnier; V Legrand; E Garcia; C Macaya; E Sousa; W van der Giessen; A Colombo; R Seabra-Gomes; F Kiemeneij; P Ruygrok; J Ormiston; H Emanuelsson; J Fajadet; M Haude; S Klugmann; M A Morel
Journal:  Lancet       Date:  1998-08-29       Impact factor: 79.321

8.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

9.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

10.  Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action.

Authors:  R Bar-Shavit; M Benezra; A Eldor; E Hy-Am; J W Fenton; G D Wilner; I Vlodavsky
Journal:  Cell Regul       Date:  1990-05
View more
  1 in total

1.  microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis.

Authors:  Gaetano Santulli
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.